New insights about <em>Candida auris</em>
12 July 2021
6. Fungal infection & disease, 1,5-hour Oral Session
•
S35
•
10:45
>
12:15
•
New insights about Candida auris
•
6. Fungal infections
10:45
•
1066
•
Characterisation of the differential pathogenicity of <em>Candida auris</em> in a <em>Galleria mellonella</em> infection model
>
V.
Victor
GARCIA-BUSTOS (Valencia)
10:55
•
618
•
Mannitol salt agar auris: a useful medium for differentiating <em>Candida auris</em>
>
T.
Teresa
NASCIMENTO (Lisbon)
11:15
•
381
•
Use of remote video auditing (RVA) in prevention of nosocomial transmission of <em>Candida auris</em>
>
A.
Akshay
KHATRI (Manhasset, New York)
11:25
•
1928
•
Antifungal activity of nitroxoline against <em>Candida auris </em>isolates
>
F.
Frieder
FUCHS (Cologne)
11:35
•
1937
•
Outcomes of oral ibrexafungerp in the treatment of ten patients with <em>Candida auris </em>infections, from the CARES Study
>
N.
Nkechi E
AZIE (Jersey City)
11:45
•
662
•
Clinical efficacy and safety of the novel antifungal fosmanogepix in patients with candidaemia and/or invasive candidiasis caused by <em>Candida auris</em>: results from a phase II proof of concept trial
>
B.
Bart Jan
KULLBERG (Nijmegen)
11:55
•
INT84
•
Q&A/Discussion
|